Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up

Teva’s Q3 2026 adjusted EPS of $0.86 beat the $0.72 consensus, and revenue of $4.40 billion topped the $4.24 billion estimate, although revenue fell 2% year over year as generic sales weakened. Teva raised 2026 revenue guidance to $16.7–$17.0 billion and increased forecasts for Austedo, Ajovy and Uzedy; shares rose 3% after the results and outlook update. Branded-drug growth lifted adjusted gross margin 345 bps to 58.7%, while FDA approval of Weltruza adds to the injectable schizophrenia portfolio; the company expects combined peak sales of $1.5–$2.0 billion for Weltruza and Uzedy.

Analysis

The key question is whether Teva can convert branded growth into durable cash generation before generic erosion overwhelms it. The margin expansion is mix-dependent: a slowdown in Austedo or launch underperformance at Uzedy/Weltruza could expose the weaker generic base and reverse operating leverage. Ajovy’s reported growth also needs parsing—reduced sales allowances mean net-price improvement contributes alongside volume, and may not recur at the same pace.

The guidance profile is less bullish than the revenue headline: revenue and free-cash-flow floors moved up, but the operating-income and EBITDA ceilings came down. That argues for improved visibility at the low end, not a clean acceleration in earnings power. With the stock already substantially ahead of the sector this year, the near-term beat may be partly discounted; the next 1–3 months hinge on launch execution, prescription trends, and whether cash conversion validates the branded-growth narrative.

Over 6–18 months, Weltruza/U zedy adoption and U.S. biosimilar commercialization could diversify growth, but peak-sales estimates are company expectations, not evidence of realized demand. Biosimilar rights transfer timing and access are meaningful execution gates. The principal falsifiers are decelerating branded prescription growth, continued U.S. generic weakness without offsetting cash flow, or a reduction in 2026 operating-income guidance. The discontinued emrusolmin study is a reminder that pipeline breadth does not eliminate asset-level failure risk.

Key Decisions for Investors

• Do not chase TEVA after the post-results move. For existing exposure, hold only while branded prescription momentum and free-cash-flow delivery remain intact; reassess on the next quarterly update if either weakens.
• Consider a staged TEVA entry on a pullback rather than an outright event-driven add. The upside case is continued branded mix improvement and launch contribution; downside is multiple compression if generic erosion or launch costs prevent cash-flow conversion.
• Track monthly/quarterly prescription data for Austedo, Ajovy, Uzedy and early Weltruza uptake, plus payer access and net pricing. Treat slower uptake or rising discounting as an alert to reduce exposure, not as a reason to extrapolate peak-sales targets.
• Monitor the biosimilar agreement’s closing and commercialization milestones, especially the later transfer of infliximab-abda rights. Until access, launch economics and contribution are clearer, do not capitalize the deal as near-term earnings upside.
• No actionable read-through to TGTX or TARS from this Teva report. For BioXcel Therapeutics, the asset transaction may be relevant, but deal economics and cash proceeds are absent; verify terms before assigning value.